The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
ATM and ATR as therapeutic targets in cancer
Open accessAbstract
In order to maintain genomic stability, cells have developed sophisticated signalling pathways to enable DNA damage or DNA replication stress to be resolved. Key mediators of this DNA damage response (DDR) are the ATM and ATR kinases, which induce cell cycle arrest and facilitate DNA repair via their downstream targets. Inhibiting the DDR has become an attractive therapeutic concept in cancer therapy, since (i) resistance to genotoxic therapies has been associated with increased DDR signalling, and (ii) many cancers have defects in certain components of the DDR rendering them highly dependent on the remaining DDR pathways for survival. ATM and ATR act as the apical regulators of the response to DNA double strand breaks and replication stress, respectively, with overlapping but non-redundant activities. Highly selective small molecule inhibitors of ATM and ATR are currently in preclinical and clinical development, respectively. Preclinical data have provided a strong rationale for clinical testing of these compounds both in combination with radio- or chemotherapy, and in synthetic lethal approaches to treat tumours with deficiencies in certain DDR components. Whole genome sequencing studies have reported that mutations in DDR genes occur with a high frequency in many common tumour types, suggesting that a synthetic lethal approach with ATM or ATR inhibitors could have widespread utility, providing that appropriate biomarkers are developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–210 of 210
Bobola, M. S., Kolstoe, D. D., Blank, A., Chamberlain, M. C., & Silber, J. R. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00176 · Cited by 62
Riesterer, O., Matsumoto, F., Wang, L., Pickett, J., Molkentine, D. P., Giri, U. P., Milas, L., & Raju, U. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9361-2 · Cited by 56
Jacquemin, V., Rieunier, G., Jacob, S., Bellanger, D., d’Enghien, C. D., Laugé, A., Stoppa‐Lyonnet, D., & Stern, M. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.196 · Cited by 55
Di Virgilio, M., Ying, C. Y., & Gautier, J. (2009) · DNA Repair · doi:10.1016/j.dnarep.2009.07.006 · Cited by 52
MRE11 expression is impaired in gastric cancer with microsatellite instability
Ottini, L. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh257 · Cited by 52
Bracey, T. S., Williams, A. C., & Paraskeva, C. (1997) · PubMed · Cited by 51
Development of a Cell-Based, High-Throughput Screening Assay for ATM Kinase Inhibitors
Guo, K., Shelat, A. A., Guy, R. K., & Kastan, M. B. (2014) · SLAS DISCOVERY · doi:10.1177/1087057113520325 · Cited by 44
The role of ATM and 53BP1 as predictive markers in cervical cancer
Roossink, F., Wieringa, H. W., Noordhuis, M. G., ten Hoor, K. A., Kok, M., Slagter‐Menkema, L., Hollema, H., de Bock, G. H., Pras, E., de Vries, E. G. E., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27488 · Cited by 39
Why RECIST Works and Why It Should Stay—Counterpoint
Fojo, A. T., & Noonan, A. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0733 · Cited by 30
Subramanian, L., & Nakamura, T. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000839 · Cited by 16
Cited by
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Genomic complexity of multiple myeloma and its clinical implications
Manier, S., Salem, K. Z., Park, J., Landau, D. A., Getz, G., & Ghobrial, I. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.122 · Cited by 560
Molecular mechanisms of tumor resistance to radiotherapy
Wu, Y., Song, Y., Wang, R., & Wang, T. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01801-2 · Cited by 527
Metadata
- Authors
- Weber, A. M., & Ryan, A. J.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 149
- Pages
- 124-138
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2061197983
- Cited by
- 635
- References
- 210
- FWCI
- 16.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.